SCHEMBL3688057

SCHEMBL3688057

CN(C)CCOc1ccc(CNC(=O)c2nc3c(C(F)(F)F)cc(-c4ccco4)cn3c2Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 2/20 0.40
PKM P14618 1/20 0.40
ALDH1A1 P00352 3/20 0.40
DRD2 P14416 2/20 0.40
DRD3 P35462 2/20 0.40
CYP2C19 P33261 2/20 0.40
HRH3 Q9Y5N1 1/20 0.40
LMNA P02545 1/20 0.40
ACHE P22303 1/20 0.40
SLC6A2 P23975 1/20 0.40
KCNH2 Q12809 1/20 0.40
MAPK1 P28482 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ADORA2A P29274 5/20 0.38
ADORA1 P30542 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3694815 0.89 ALDH1A1 (0.51) RXFP1PKMALDH1A1CYP2C19LMNA
SCHEMBL3649036 0.88 CACNA1G (0.39) RXFP1PKMALDH1A1CYP2C19KCNH2
SCHEMBL3701613 0.87 PKM (0.44) RXFP1PKMALDH1A1CYP2C19MAPK1
SCHEMBL3702560 0.85 ADORA2A (0.46) RXFP1PKMALDH1A1MAPK1SMN1; SMN2
SCHEMBL3696233 0.85 PKM (0.49) RXFP1PKMALDH1A1MAPK1SMN1; SMN2
SCHEMBL7495068 0.84 PKM (0.46) RXFP1PKMALDH1A1CYP2C19MAPK1
SCHEMBL3703954 0.83 ADORA3 (0.49) RXFP1PKMALDH1A1CYP2C19SMN1; SMN2
SCHEMBL7490205 0.81 RXFP1 (0.45) RXFP1PKMALDH1A1CYP2C19MAPK1
SCHEMBL3701552 0.81 ABCB1 (0.45) RXFP1PKMMAPK1ADORA2AADORA1
SCHEMBL7490436 0.81 ALDH1A1 (0.48) RXFP1PKMALDH1A1CYP2C19MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
EP-2187883-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2010-05-26 EP disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
WO-2009023179-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections OAT, HAVCR2, CPS1 RXFP1 4676/4885PKM 2286/4885ALDH1A1 1337/4885
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections OAT, HAVCR2, CPS1 RXFP1 4676/4885PKM 2286/4885ALDH1A1 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.